Tempe, Arizona-based Align Technology, Inc. (ALGN) is a leader in medical devices, renowned for its Invisalign clear aligners and iTero intraoral scanners. With a market cap of $14.1 billion, Align has revolutionized orthodontics and digital dentistry with its innovative solutions. The healthcare major is set to unveil its second-quarter results after the market closes on Wednesday, Jul. 30.

Ahead of the event, analysts expect ALGN to report non-GAAP earnings of $2.10 per share, up 18% from the profit of $1.78 per share reported in the year-ago quarter. The company has surpassed the Street’s bottom-line projections in one of the past four quarters, while missing on three other occasions.

For the full fiscal 2025, its earnings are expected to come in at $8.41 per share, up 20% from $7.01 per share reported in the year-ago quarter. While in fiscal 2026, its earnings are expected to rise 9.8% year-over-year to $9.23 per share.

ALGN stock has declined 17.8% over the past 52 weeks, underperforming the Health Care Select Sector SPDR Fund’s (XLV) 6.3% decline and the S&P 500 Index’s ($SPX) 13% uptick during the same time frame.

Align Technology's stock prices rose 2% in the trading session after the release of its mixed Q1 earnings on Apr. 30. The company’s net revenues declined 1.8% year-over-year to $979.3 million, but surpassed the Wall Street estimates. Its non-GAAP gross margin came in at 70.2%, down from 70.5% in the year-ago quarter, leading to a 2.3% drop in non-GAAP gross profit to $687.4 million. Furthermore, ALGN’s non-GAAP adjusted net income declined 2.8% year-over-year to $156.9 million, but surpassed the consensus estimates by a thin margin.

The stock holds a consensus “Moderate Buy” rating overall. Of the 13 analysts covering the stock, opinions include nine “Strong Buys,” one “Moderate Buy,” two “Holds,” and one “Moderate Sell.” Its mean price target of $234.25 suggests an 18.9% upside potential from current price levels.